Enhancing NAD+ Salvage Pathway Reverts the Toxicity of Primary Astrocytes Expressing Amyotrophic Lateral Sclerosis-linked Mutant Superoxide Dismutase 1 (SOD1)
Overview
Affiliations
Nicotinamide adenine dinucleotide (NAD(+)) participates in redox reactions and NAD(+)-dependent signaling pathways. Although the redox reactions are critical for efficient mitochondrial metabolism, they are not accompanied by any net consumption of the nucleotide. On the contrary, NAD(+)-dependent signaling processes lead to its degradation. Three distinct families of enzymes consume NAD(+) as substrate: poly(ADP-ribose) polymerases, ADP-ribosyl cyclases (CD38 and CD157), and sirtuins (SIRT1-7). Because all of the above enzymes generate nicotinamide as a byproduct, mammalian cells have evolved an NAD(+) salvage pathway capable of resynthesizing NAD(+) from nicotinamide. Overexpression of the rate-limiting enzyme in this pathway, nicotinamide phosphoribosyltransferase, increases total and mitochondrial NAD(+) levels in astrocytes. Moreover, targeting nicotinamide phosphoribosyltransferase to the mitochondria also enhances NAD(+) salvage pathway in astrocytes. Supplementation with the NAD(+) precursors nicotinamide mononucleotide and nicotinamide riboside also increases NAD(+) levels in astrocytes. Amyotrophic lateral sclerosis (ALS) is caused by the progressive degeneration of motor neurons in the spinal cord, brain stem, and motor cortex. Superoxide dismutase 1 (SOD1) mutations account for up to 20% of familial ALS and 1-2% of apparently sporadic ALS cases. Primary astrocytes isolated from mutant human superoxide dismutase 1-overexpressing mice as well as human post-mortem ALS spinal cord-derived astrocytes induce motor neuron death in co-culture. Increasing total and mitochondrial NAD(+) content in ALS astrocytes increases oxidative stress resistance and reverts their toxicity toward co-cultured motor neurons. Taken together, our results suggest that enhancing the NAD(+) salvage pathway in astrocytes could be a potential therapeutic target to prevent astrocyte-mediated motor neuron death in ALS.
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
Berry J, Maragakis N, Macklin E, Chibnik L, Quintana M, Saville B JAMA. 2025; .
PMID: 40067821 PMC: 11833661. DOI: 10.1001/jama.2024.27643.
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases.
Chen L, Shen Q, Liu Y, Zhang Y, Sun L, Ma X Signal Transduct Target Ther. 2025; 10(1):31.
PMID: 39894843 PMC: 11788444. DOI: 10.1038/s41392-024-02071-0.
The function of nicotinamide phosphoribosyl transferase (NAMPT) and its role in diseases.
Peng A, Li J, Xing J, Yao Y, Niu X, Zhang K Front Mol Biosci. 2024; 11:1480617.
PMID: 39513038 PMC: 11540786. DOI: 10.3389/fmolb.2024.1480617.
Potential Therapeutic Interventions Targeting NAD Metabolism for ALS.
Lundt S, Ding S Cells. 2024; 13(17.
PMID: 39273079 PMC: 11394323. DOI: 10.3390/cells13171509.
Pal A, Grossmann D, Glass H, Zimyanin V, GuNTHER R, Catinozzi M Life Sci Alliance. 2024; 7(8).
PMID: 38760174 PMC: 11101837. DOI: 10.26508/lsa.202302535.